| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Dacopafant
CAS:125372-33-0
Package:50mg/RMB 13800;100mg/RMB 17500;25mg/RMB 10600
|
AIDS029690 manufacturers
- Dacopafant
-
- $1980.00
-
2026-05-11
- CAS:125372-33-0
- Purity:
- Supply Ability: 10g
|
| | AIDS029690 Basic information |
| Product Name: | AIDS029690 | | Synonyms: | AIDS029690;1H,3H-Pyrrolo[1,2-C]thiazole-7-carboxamide, 3-(3-pyridinyl)-, (3R)-;Acopafant;Rp 55778;UNII-H1T03Z1G60 | | CAS: | 125372-33-0 | | MF: | C12H11N3OS | | MW: | 245.3 | | EINECS: | | | Product Categories: | | | Mol File: | 125372-33-0.mol |  |
| | AIDS029690 Chemical Properties |
| Boiling point | 516.4±50.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | pka | 16.43±0.40(Predicted) |
| | AIDS029690 Usage And Synthesis |
| Uses | Acopafant (Dacopafant; RP 55778) is a potent platelet-activating factor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection[1]. | | References | [1] Weissman D, . A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2537-41. DOI:10.1073/pnas.90.6.2537 |
| | AIDS029690 Preparation Products And Raw materials |
|